Fig 1 - uploaded by Ata Ghadiri
Content may be subject to copyright.
Genetic map of the long arm of X chromosome has shown with genetic distances in centimorgans. HPRT, DXS51, FIX, FVIII, St14, DX13 and fragile X site are shown. 

Genetic map of the long arm of X chromosome has shown with genetic distances in centimorgans. HPRT, DXS51, FIX, FVIII, St14, DX13 and fragile X site are shown. 

Source publication
Article
Full-text available
Hemophilia B is factor IX deficiency and is inherited as X-linked recessive disorder. The subject of carrier detection in hemophilias has received new impetus in the last several years. Analysis of factor IX gene polymorphisms is considered the best approach for prenatal diagnosis and hemophilia B carrier detection, if the identification of the gen...

Contexts in source publication

Context 1
... B (Christmas disease) is an X- linked recessive bleeding disorder caused by a deficiency or an abnormality of coagulation factor IX. Its birth frequency is about 1 male in every 30000 (1). According to the latest statistical figures, there are approximately 700 hemophilia B affected individuals in Iran (2). A total of eight intragenic RFLP within the factor IX gene have been characterized (3). Hemophilia B carrier detection using both intragenic and extragenic RFLP have been performed (3). A prenatal diagnosis of hemophilia B using intragenic Taq I site has been carried out (4). In families where the mutation has been characterized, direct detection of the gene defect can be applied to carrier and prenatal diagnosis (5, 6). Hemophilia B is less frequent than hemophilia A and is about 1 in 6. Eight-percent factor IX gene mutations are sporadic. The location of the factor IX gene has been narrowed down to the distal portion of band Xq27 (7) ( Fig. 1). The human factor IX gene consists of eight exons and seven introns, spaced out over some 33 kb of chromosomal DNA, which is transcribed to a mRNA of 2803bp (7). Eight intragenic RFLPs which are BamH1, Hhal, Ddel, XmnI, Taq1, MnII, MspI, MseI which are located across a 20 kb region between exons I and VI (3) (Fig. 2). These RFLPs are used for carrier detection and prenatal diangosis (8). The Xmn I have been shown to be in strong linkage disequilibrium with the Taq I polymorphism (8). The frequencies of these intragenic RFLP are high in European populations but low in non- European populations. The second polymorphic sites have been used for carrier detections and prenatal diagnosis, have been performed in Russia (9) using Taq I and Ddel RFLP and also carrier detection are done in Japan using two dinucleotide RFLPs (F9 – 793, F9 – 192) and Hhal RFLP (10). This study presents the results of RFLP analysis for two intragenic polymorphisms in the Iranian hemophilia B families. This is the first investigation of RFLP analysis and carrier detection for hemophilia B in ...
Context 2
... the mutation has been characterized, direct detection of the gene defect can be applied to carrier and prenatal diagnosis (5,6). Hemophilia B is less frequent than hemophilia A and is about 1 in 6. Eight-percent factor IX gene mutations are sporadic. The location of the factor IX gene has been narrowed down to the distal portion of band Xq27 (7) (Fig. 1). The human factor IX gene consists of eight exons and seven introns, spaced out over some 33 kb of chromosomal DNA, which is transcribed to a mRNA of 2803bp (7). Eight intragenic RFLPs which are BamH1, Hhal, Ddel, XmnI, Taq1, MnII, MspI, MseI which are located across a 20 kb region between exons I and VI (3) (Fig. 2). These RFLPs are ...

Similar publications

Article
Full-text available
A global phase 3 study evaluated the pharmacokinetics, efficacy, and safety of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in 63 previously treated male patients (12-61 years) with severe hemophilia B (factor IX [FIX] activity ≤2%). The study included 2 groups: group 1 patients received routine prophylaxis once ev...
Article
Full-text available
Diffuse alveolar hemorrhage (DAH) is a life-threatening complication that occurs in association with various diseases including coagulation disorders. In rare cases, it is caused by hemophilia. A 48-year-old man was admitted to our hospital for a third time due to DAH. Although the cause of DAH could not be identified by bronchoscopy or laboratory...
Article
Full-text available
BACKGROUND: Enhanced pharmacokinetic profile of albutrepenonacog alfa allows to prolong the interdose period in prophylaxis, maintaining higher trough level, and to reduce dosage needed for bleeding. This improvement could lead to a better efficiency of the hemophilia B treatment. OBJECTIVES: To estimate the impact of this new drug on the Italian N...
Article
Full-text available
A recombinant coagulation factor IX albumin fusion protein (rIX-FP, CSL654) was developed with an improved PK profile to support a longer dosing interval for routine prophylaxis treatment. Japanese subjects have participated in a Study CSL654_3001, phase 3 open label, multinational, pivotal study of rIX-FP. Male hemophilia B patients with no inhibi...
Article
Full-text available
A recombinant fusion protein linking coagulation factor IX (FIX) with human albumin (rIX-FP) has been developed to facilitate hemophilia B treatment by less frequent FIX dosing. This first-in-human dose-escalation trial in 25 previously treated subjects with hemophilia B (FIX ≤ 2 IU/dL) examined the safety and pharmacokinetics of 25, 50, and 75 IU/...